Compass Pathways reports achieving the primary endpoint in Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression

COMP360 psilocybin Phase 3 results report achievement of the primary endpoint for treatment-resistant depression. The update frames this as success in the first phase 3 trial phase, which evaluates COMP360 in patients with treatment-resistant depression using a psilocybin-based therapy program. The news positions the outcome as an important clinical milestone for Compass Pathways and supports continued development of psilocybin treatment as a potential option for people who have not responded adequately to existing therapies.